Allergy Immunotherapy Market size was over USD 1.85 billion in 2024 and is likely to reach USD 5.81 billion by the end of 2037, witnessing around 9.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of allergy immunotherapy is assessed at USD 1.99 billion.
Because more people are developing these allergies, the market is expanding. The healthcare system is challenged by complex allergies, which cause people's health to deteriorate too much. Asthma and other allergies that affect the body's respiratory system are on the rise as a result of the environment's increasing air pollution. As per a recent report, asthma was the primary diagnosis in 38,792 hospitalizations between 2017 and 2018. Also, Asthma-related fatalities totaled 417 in 2020.
Furthermore, a rising number of immunotherapy treatments are under development to treat patients' allergies. This element is anticipated to fuel market expansion. Sublingual immunotherapy has been investigated by certain researchers for a variety of food allergies, including those to milk, peanuts, kiwis, and peaches. Numerous studies have shown that therapy cannot be effective without consistent pharmaceutical use.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.2% |
|
Base Year Market Size (2024) |
USD 1.85 billion |
|
Forecast Year Market Size (2037) |
USD 5.81 billion |
|
Regional Scope |
|
Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis)
The rhinitis segment is expected to hold a significant share of the allergy immunotherapy market during the forecast period. According to a survey, rhinitis and asthma impact 23 million people in the US each year. In the same region, an additional 50 million people suffer from another type of allergy. One of the major drivers of the market expansion is the increased investment made by major manufacturers in the development of AIT medications to treat different allergies. Therefore, it is anticipated that allergic rhinitis will fuel the segment's expansion.
Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy)
The subcutaneous immunotherapy segment would account for more than 53% of the allergy immunotherapy market. Subcutaneous immunotherapy (SCIT) is a cutting-edge method for treating allergic diseases because it alters allergic diseases by concentrating on the underlying immunological mechanism. Numerous carefully monitored clinical trials have demonstrated its efficacy and safety in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and hypersensitivity to stinging insects. Subcutaneous immunotherapy (SCIT), which is administered via injection, is frequently referred to as an "allergy shot". It provides symptomatic relief for those with asthma and allergic rhinitis and is the standard treatment for allergen desensitization. Increased prevalence of allergic disorders and high demand for improved procedures are some of the factors driving the growth of the segment. According to estimates, between 11 and 26 million people in Europe have food allergies. With a population of 7 billion people, this rate amounts to 240–550 million people who could be food allergies, which is a significant global health burden.
Our in-depth analysis of the global market includes the following segments:
|
Treatment |
|
|
Allergy Type |
|
|
Distribution Channels |
|
APAC Market Forecast
In the Asia Pacific allergy immunotherapy market is to generate the highest revenue by the end of 2037. Also, Asia Pacific is expected to hold a share of 36% during the forecast period. In countries, such as India and China, this is mainly due to the existence of a large proportion of the younger population that are more susceptible to sensitization. Moreover, a number of factors contributing to growth in this market in the Asia Pacific region are the presence of major key players in the market, investment from them, and uptake of medicines like Sublingual Immunotherapy with an overview of long-term results as well as dosage standardization.
North American Market Statistics
North America allergy immunotherapy market is expected to hold a significant share of 27% during the forecast period. The market expansion can be attributed to the region's high frequency of allergy diseases as well as the population's increased health consciousness. According to the World Allergy Organization, allergic rhinitis is the seventh most common chronic respiratory condition in the US, affecting 10–30% of the general adult population and approximately 405 children. A few other elements boosting the expansion in the area include high-end research and development, investments made by market participants, partnerships and acquisitions with significant industry participants, and strong emphasis on manufacturing facilities.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?